Reseatch progress on the role and regulatory mechanism of fructose-1,6-bisphosphatase 1 in tumors occurrence and development

doi:10.16098/j.issn.0529-1356.2025.02.016

PDF(754 KB)

Acta Anatomica Sinica ›› 2025, Vol. 56 ›› Issue (2) : 248-251. DOI: 10.16098/j.issn.0529-1356.2025.02.016

Review

Reseatch progress on the role and regulatory mechanism of fructose-1,6-bisphosphatase 1 in tumors occurrence and development

SUN Bo-wen CHENG Yuan^*
#br#

Author information +

History +

Abstract

The metabolic enzyme fructose-1,6-bisphosphatase 1 (FBP1) plays an important role in tumour development. In a variety of tumors, the high expression level of FBP1 has been correlated with a good prognosis. FBP1 can regulate the tumor cell metabolism reprograming by inhibiting glycolysis and fat metabolism, play the roles of protein phosphatase by regulating the NF-κB pathway and block tumor progression by regulating tumour immune cell infiltration. However, FBP1 promote malignant progression in a few tumors, some of the regulatory mechanisms are still unclear and need to be followed up with further research.

Key words

Fructose-1,6-bisphosphatase 1 / Tumor / Metabolism / Progression

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

SUN Bo-wen CHENG Yuan. Reseatch progress on the role and regulatory mechanism of fructose-1,6-bisphosphatase 1 in tumors occurrence and development[J]. Acta Anatomica Sinica. 2025, 56(2): 248-251 https://doi.org/10.16098/j.issn.0529-1356.2025.02.016

References

［1］Hu J, Wang J, Li C, Shang Y. Fructose-1,6-bisphosphatase aggravates oxidative stress-induced apoptosis in asthma by suppressing the Nrf2 pathway［J］. J Cell Mol Med, 2021,25(11):5001-5014.

［2］ Wang Z, Li M, Jiang H, et al. Fructose-1,6-bisphosphatase 1 functions as a protein phosphatase to dephosphorylate histone H3 and suppresses PPARα-regulated gene transcription and tumour growth［J］. Nat Cell Biol, 2022,24(11):1655-1665.

［3］ Wang B, Zhou Y, Zhang J, et al. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity［J］. Theranostics, 2020,10(3):1033-1045.

［4］ Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2021,71(3):209-249.

［5］ Ke G, Cheng N, Sun H, et al. Explore the impact of hypoxia-related genes (HRGs) in cutaneous melanoma［J］. BMC Med Genomics, 2023,16(1):160.

［6］ Luo D, Yang Q, Wang H, et al. A predictive model for assessing prognostic risks in gastric cancer patients using gene expression and methylation data［J］. BMC Med Genomics, 2021,14(1):14.

［7］ Sun H, Zhang H, Jing L, et al. FBP1 is a potential prognostic biomarker and correlated with tumor immunosuppressive microenvironment in glioblastoma［J］. Neurosurg Rev, 2023,46(1):187.

［8］ Li H, Qi Z, Niu Y, et al. FBP1 regulates proliferation, metastasis, and chemoresistance by participating in C-MYC/STAT3 signaling axis in ovarian cancer［J］. Oncogene, 2021,40(40):5938-5949.

［9］ Damanakis A, Plum PS, Gebauer F, et al. Fructose-1,6-bisphosphatase 1 (FBP1) is an independent biomarker associated with a favorable prognosis in esophageal adenocarcinoma［J］. J Cancer Res Clin Oncol, 2022,148(9):2287-2293.

［10］ Stachowiak M, Szymanski M, Ornoch A, et al. SWI/SNF chromatin remodeling complex and glucose metabolism are deregulated in advanced bladder cancer［J］. IUBMB Life, 2020,72(6):1175-1188.

［11］ Yang X, Tang W, He Y, et al. A novel fatty-acid metabolism-based classification for triple negative breast cancer［J］. Aging (Albany NY), 2023,15(4):1177-1198.

［12］ Liu M, Pan Q, Xiao R, et al. A cluster of metabolism-related genes predict prognosis and progression of clear cell renal cell carcinoma［J］. Sci Rep, 2020,10(1):12949.

［13］ Cho ES, Kim NH, Yun JS, et al. Breast cancer subtypes underlying EMT-mediated catabolic metabolism［J］. Cells, 2020,9(9):2064.

［14］ Wang Z, He T, Lv W, et al. Down-regulation of FBP1 in lung adenocarcinoma cells promotes proliferation and invasion through SLUG mediated epithelial mesenchymal transformation［J］. Transl Cancer Res, 2023,12(2):236-246.

［15］ Son B, Lee S, Kim H, et al. Decreased FBP1 expression rewires metabolic processes affecting aggressiveness of glioblastoma［J］. Oncogene, 2020,39(1):36-49.

［16］ Yang LN, Ning ZY, Wang L, et al. HSF2 regulates aerobic glycolysis by suppression of FBP1 in hepatocellular carcinoma［J］. Am J Cancer Res, 2019,9(8):1607-1621.

［17］ Liao K, Deng S, Xu L, et al. A feedback circuitry between polycomb signaling and fructose-1, 6-bisphosphatase enables hepatic and renal tumorigenesis［J］. Cancer Res, 2020,80(4):675-688.

［18］ Xu Y, Tran L, Tang J, et al. FBP1-altered carbohydrate metabolism reduces leukemic viability through activating P53 and modulating the mitochondrial quality control system in vitro［J］. Int J Mol Sci, 2022,23(19):11387.

［19］ He Y, Hua R, Li B, et al. Loss of FBP1 promotes proliferation, migration, and invasion by regulating fatty acid metabolism in esophageal squamous cell carcinoma［J］. Aging (Albany NY), 2020,13(4):4986-4998.

［20］ Li F, Huangyang P, Burrows M, et al. FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome［J］. Nat Cell Biol, 2020,22(6):728-739.

［21］ Zhu W, Chu H, Zhang Y, et al. Fructose-1,6-bisphosphatase 1 dephosphorylates IκBα and suppresses colorectal tumorigenesis［J］. Cell Res, 2023,33(3):245-257.

［22］ Lu C, Ren C, Yang T, et al. Fructose-1, 6-bisphosphatase 1 interacts with NF-κB p65 to regulate breast tumorigenesis via PIM2 induced phosphorylation［J］. Theranostics,2020,10(19):8606-8618.

［23］ Wang Z, Li M, Jiang H, et al. Fructose-1,6-bisphosphatase 1 functions as a protein phosphatase to dephosphorylate histone H3 and suppresses PPARα-regulated gene transcription and tumour growth［J］. Nat Cell Biol, 2022,24(11):1655-1665.

［24］ Yang C, Zhu S, Yang H, et al. FBP1 binds to the bromodomain of BRD4 to inhibit pancreatic cancer progression［J］. Am J Cancer Res, 2020,10(2):523-535.

［25］ Dai Z, Liu T, Liu G, et al. Identification of clinical and tumor microenvironment characteristics of hypoxia-related risk signature in lung adenocarcinoma［J］. Front Mol Biosci, 2021,8(1):75742.

［26］ Liu Z, You Y, Chen Q, et al. Extracellular vesicle-mediated communication between hepatocytes and natural killer cells promotes hepatocellular tumorigenesis［J］. Mol Ther, 2022,30(2):606-620.

［27］ Ma J, Guo Z, Yang X, et al. Exploration of various roles of hypoxia genes in osteosarcoma［J］. Sci Rep, 2022,12(1):18293.

［28］ Chen L, Yuan R, Wen C, et al. E3 ubiquitin ligase UBR5 promotes pancreatic cancer growth and aerobic glycolysis by downregulating FBP1 via destabilization of C/EBPα［J］. Oncogene, 2021,40(2):262-276.

［29］ Yang C, Zhu S, Yang H, et al. USP44 suppresses pancreatic cancer progression and overcomes gemcitabine resistance by deubiquitinating FBP1［J］. Am J Cancer Res, 2019,9(8):1722-1733.

［30］ Cheng X, Zhang B, Guo F, et al. Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors［J］. Mol Oncol, 2022,16(7):1591-1607.

［31］ Zhang X, Li S, He J, et al. TET2 suppresses VHL deficiency-driven clear cell renal cell carcinoma by inhibiting HIF signaling［J］. Cancer Res, 2022,82(11):2097-2109.

［32］ Li L, Yang L, Fan Z, et al. Hypoxia-induced GBE1 expression promotes tumor progression through metabolic reprogramming in lung adenocarcinoma［J］. Signal Transduct Target Ther, 2020,5(1):54.

［33］ Franke CM, Gu VW, Grimm BG, et al. TFAP2C regulates carbonic anhydrase XII in human breast cancer［J］. Oncogene, 2020,39(6):1290-1301.

［34］ Zou J, Zhu X, Xiang D, et al. LIX1-like protein promotes liver cancer progression via miR-21-3p-mediated inhibition of fructose-1,6-bisphosphatase［J］. Acta Pharm Sin B, 2021,11(6):1578-1591.

［35］ Zhao W, Zhao J, Guo X, et al. LncRNA MT1JP plays a protective role in intrahepatic cholangiocarcinoma by regulating miR-18a-5p/FBP1 axis［J］. BMC Cancer,2021,21(1):142.

［36］ Pan Z, Cai J, Lin J, et al. A novel protein encoded by circFNDC3B inhibits tumor progression and EMT through regulating Snail in colon cancer［J］. Mol Cancer, 2020,19(1):71.

［37］ Yang X, Zhao L, Pei J, et al. CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA［J］. Breast Cancer Res Treat, 2020,183(1):71-82.

［38］ Yang C, Zhu S, Yang H, et al. FBP1 binds to the bromodomain of BRD4 to inhibit pancreatic cancer progression［J］. Am J Cancer Res, 2020,10(2):523-553.